

XXIXth Meeting of the Club Jules Gonin

3–6 September 2014 • Zürich, Switzerland



PRELIMINARY PROGRAMME

XXIXth Meeting of the Club Jules Gonin

3–6 September 2014 • Zürich, Switzerland

Executive Committee

President: Yannick LeMer

Vice-President: Bill Aylward

Secretary:

Thomas J. Wolfensberger

Members:

Gary Abrams
Susanne Binder
Borja Corcostegui
Sven Crafoord
Michel Eid Farah
Tatsuro Ishibashi
Michael Trese

Meeting Organiser

Thomas J. Wolfensberger

Club Meeting Secretariat

Denis Tarantola

Scientific Programme Committee

Chairmen:

Gary Abrams, Michael Trese

Members

Susanne Binder
Sven Crafoord
Michel Eid Farah

Club Jules Gonin

Av. de France 15
CH-1004 Lausanne, Switzerland
Tel: +41-21-626 8830
Fax: +41-21-626 8831

www.clubjulesgonin.com

Welcome


Dear Colleagues,

It is my great pleasure to welcome you to Zürich for the XXIXth Meeting of the Club Jules Gonin. After the last meeting in Reykjavik brought us to the stark beauty of the North, this year's meeting will introduce us to the refined unofficial capital of Switzerland.

Known as Turicum during the times of the Romans, Zürich boasts a history that stretches over more than 2000 years, and during the past century the city has developed into the cultural and economic hub of Switzerland.

The Kongresshaus, where the meeting will take place, is located right next to the lake shore providing an ideal framework for the scientific programme, and during the social hours we will introduce you simply to the best that Zürich has to offer. The vast choice of hotels are all within walking distance of the meeting venue and of the old town center.

We very much look forward to seeing you in Zürich in September 2014.



Thomas J. Wolfensberger, MD
Secretary Club Jules Gonin



Synopsis of Programme

Time	Wednesday 3 September	Thursday 4 September	Friday 5 September	Saturday 6 September
07:30			Business Meeting 07:30–08:15	
08:00		AMD 08:00–09:50		Diabetes-Vascular II 08:00–08:30
08:30			Wacker Lecture Gonin Lecture Tano Lecture Gragoudas Award 08:30–10:00	Rapid Fire: Diabetes-Vascular 08:30–08:55
09:00				Pediatric Retina Dystrophies 08:55–09:45
09:30				
10:00		Coffee Break 09:50–10:20	Coffee Break 10:00–10:30	Coffee Break 09:45–10:15
10:30		Retinal Imaging 10:20–11:50	Tumors 10:30–11:30	Vitreoretinal Surgery III 10:15–11:15
11:00			Rapid Fire: Tumors 11:30–12:15	Rapid Fire: Vitreoretinal Surgery 11:15–12:15
11:30				
12:00		Rapid Fire: AMD-Retinal Imaging 11:50–13:00	Lunch 12:15–13:30	Lunch 12:15–13:30
12:30		Lunch 13:00–14:00		
13:00				
13:30				Inflammation 13:30–14:10
14:00	Company sponsored Symposium 14:00–15:00	Vitreoretinal Surgery I 14:00–15:00	Vitreoretinal Surgery II 13:30–15:00	Rapid Fire: Pediatric Inflammation 14:10–14:30 Rapid Fire: Clinical Studies 14:30–15:00
14:30				
15:00	Company sponsored Symposium 15:00–16:00	Networking Boat departure Bürkliplatz 15:45	Coffee Break 15:00–15:30	Coffee Break 15:00–15:20
15:30			Diabetes-Vascular I 15:30–17:30	Clinical Studies 15:20–17:00
16:00	Adjourn 17:00			
16:30				Company sponsored Symposium 16:00–17:00
17:00				
17:30	Fluorescein Conference 17:00–19:00		Posters 17:30–18:45	<div><div></div> Full Paper (8+2 min)</div> <div><div></div> Rapid Fire (3+2 min)</div> <div><div></div> Posters</div>
18:00				
18:30				
19:00	Networking Reception Meisen Guild Hall 19:30–21:00	Conference Dinner Rapperswil Castle 18:30		Early Registration Deadline: 31 May 2014
19:30			Conference Dinner Bellevueplatz Zürich 19:30	

- Full Paper (8+2 min)
- Rapid Fire (3+2 min)
- Posters

**Early Registration
Deadline: 31 May 2014**

General Information

Zürich: An Historical Introduction



Known as Turicum during the times of the Romans, Zürich boasts a history that stretches over more than 2000 years. Around 15 BC a military base was established which was called Turicum, a name which was first found on a Roman grave stone excavated in the city center. Later inhabitants weren't so fluent in Latin,

and the name gradually became the slightly more germanic 'Zürich'.

In 1218, Zürich became a free city and in 1336 an uprising of Zürich's craftsmen made the newly founded guilds the foundation of Zürich's political structure. Even today people who matter in Zürich belong to one of the guilds, which celebrate the end of winter with an annual historical festival.

With Huldrych Zwingli leading the Reformation in Switzerland, 1519 marked a new era in Zürich's history and the city gained European significance in the history of the protestant church.



In the 18th century, Zürich enjoyed a cultural surge. Among the intellectuals of the time were the educational reformer Heinrich Pestalozzi, the historian Johann Jakob Bodmer and the artist Johann Heinrich Füssli.

From the mid 19th century onwards the industrialist Alfred Escher dominated Zürich and Swiss politics. He founded large railway companies and was the mastermind of the construction of the Gotthard rail tunnel, connecting Italy with Switzerland. This era brought with it not only economic growth but also saw Zürich's political and cultural influence reach a pinnacle in the newly constituted government of Switzerland during the second half of the 19th century.




The University of Zürich was founded in 1833 and since 1855, Zürich has also been home to the Federal Institute of Technology (ETH) which together have produced more than 30 Nobel prize winners.

In the past few decades Zürich has developed into the main powerhouse of the Swiss economy, mainly due to a very strong banking and insurance sector.

How to reach Zürich

By Air

Zürich Kloten International Airport is the major hub of Swiss International Airlines with direct flights from all major cities in Europe and many others around the world.



By Car

Zürich can be reached through the well developed Swiss motorway system. General road information and traffic reports from other areas in Switzerland may be viewed on the web page of the "Strasseninformation der Autobahn Schweiz" (Road Information Services of the Swiss Motorways). www.strasseninfo.ch



In order to use the Motorways in Switzerland it is mandatory for drivers to purchase the "Autobahnvignette Schweiz" (Swiss Motorway tax sticker) for CHF 40 and affix it to the inside of their windshield. The sticker is valid for a whole year and may be obtained at customs offices, gas stations and post offices.

Transfer from Zürich airport to Zürich City Centre

Train


The railway station of the Swiss Railway Network SBB at the Zürich Airport is located directly beneath the Airport Shopping area on Level -2, just minutes away from Check-Ins 1-3 as well as Arrival Halls 1+2. Trains run every 10 minutes to and from the Zürich Main Station during peak traffic times (travel time 10 minutes). The trip by train from Zürich Airport to Zürich Main Railway Station costs around CHF 6.60 (1 adult, one way). You can buy your ticket from the SBB Travel Center on Level -1 or on-line. Train time tables can be checked on www.sbb.ch.

Taxi

The journey from the airport to the city center is around 20 minutes by taxi. The taxi ranks are located directly by the exits at the Arrivals terminals 1 and 2. The trip by taxi from the airport to the center of Zürich costs around CHF 50.

Taxis in Zürich 24 hours/day

Tel. +41 (0)44 444 44 44 • www.taxi444.ch



Meeting Venue



KONGRESSHAUS ZÜRICH

Das Panorama.

The Kongresshaus is located on the shore of Lake Zürich within easy walking distance of hotels and the city centre.


Claridenstrasse 5, 8002 Zürich.

Tel: +41 (0)44 206 36 36

www.kongresshaus.ch



Floorplan



- 1 Main entrance Claridenstrasse 5
- 2 Registration and Speaker Ready Room
- 3 Gartensaal, Main Auditorium
- 4 Panoramasaal, Commercial Exhibition, Posters and Catering

Weather

The climate at this time of year in Zürich is generally mild with average temperatures between 10–18 °. As some showers may be expected, guests are recommended to bring a light coat.

Electricity

Electric current in Switzerland runs at 220 V AC. Plugs are two or three round prongs.

Registration & Hotel Reservations

Meeting Secretariat

All matters concerning registration for the meeting, hotel reservation and tour bookings will be handled by the Meeting Secretariat, Contendam. For further details regarding registration and bookings, please contact:

Club Jules Gonin

c/o Contendam
26–28 Hammersmith Grove
London W6 7HA
United Kingdom

Tel : +44 (0) 20 8748 8868

Fax: +44 (0) 20 8237 4093

Email: CJGregistration@contendam.com

Registration for Meeting

You can register online via www.clubjulesgonin.com.

Due to updated Healthcare Compliance codes which came into effect in Europe at the end of October 2013 and the beginning of 2014, it is no longer appropriate practice for medical meetings which have the support and involvement of the pharmaceutical and medical healthcare industries to include social events within the event registration fees. These are therefore offered as an option and at an additional charge to those registering.

Registration Fees in Swiss Francs (CHF)

Type of registration	Registration	Networking Session and Dinner Thursday afternoon/evening	Conference Dinner Friday evening
Early Bird Gonin Member	500	150	150
Early Bird Candidate	550	150	150
Early Bird Guest	550	150	150
Standard Gonin Member	650	150	150
Standard Candidate	690	150	150
Standard Guest	690	150	150
Early Bird Accompanying person	75	150	150
Standard Accompanying person	100	150	150
Early Bird Child 4–16 years	50	50	50
Standard Child 4–16 years	75	50	50

Methods of Payment

Registration for the meeting, hotel reservations and payments have to be made online via the Club Jules Gonin Website: www.clubjulesgonin.com MasterCard or VISA credit cards are accepted.

Cancellation Policy

Notification of cancellation of registration must be sent in writing to the Meeting Organisers, Contendam. Cancellations before 31 May 2014 will receive a full refund less a 20% administrative fee. No refunds can be made for cancellations received after the 31 May 2014, but substitutions may be made at any time.

Registration & Hotel Reservations

Registration as member, candidate or guest includes:

- Participation in the scientific programme
- Conference folder with programme
- Coffee breaks
- Lunch from Thursday 4 September – Saturday 6 September 2014
- Network Reception at the Meisen Guild Hall on 3 September 2014

For the following events individual registration and payment is needed:

- Networking session and dinner at Rapperswil Castle on Thursday 4 September 2014
- Conference Dinner in Zürich on Friday 5 September 2014
- All excursions in the accompanying person programme

Registration Desk

The registration desk at the Kongresshaus will be open at the following times:

Wednesday 3 September	13:30–19:30
Thursday 4 September	07:30–15:30
Friday 5 September	07:00–19:00
Saturday 6 September	07:30–17:00



Hotel Reservations

www.clubjulesgonin.com

Hotel reservations are made online only, via the Club's website: www.clubjulesgonin.com, which will link you to the event registration webpage. Under "Registration" on the events webpage you register for the meeting, book hotel accommodation and tours, all at the same time. When closing your registration, you will receive an e-mail confirmation. All registrations must be accompanied by the relevant payment. Please note that without payment all hotel reservations are provisional and will not be confirmed. In the event that the payment for your hotel booking is not received within 14 days of registration, the Organisers reserve the right to cancel this booking without prior notification. Notification of your accommodation booking will be sent to you with confirmation of your registration fees.

Hotel cancellation terms and conditions

Cancellations must be received by the Organising Secretariat (Contendam Ltd) in writing on or before 20 July 2014. All cancellations received before this date will be accepted with a refund minus £30 administration fee. All cancellations received after this date are non refundable as these are passed on to the hotel to secure your booking. In the event of a non arrival, at 09.00 the following day, the hotel will automatically release the reservation and pre-payments will be non refundable.

If you are booking a room, please note that on 20 July 2014 all rooms will be released and you will no longer be able to book our special rates via the registration form. Should you wish to book a room after this date, please send an email to CJGregistration@contendam.com with your request and we will try to obtain a room for you at the conference rate.



Map of Zürich with hotels



- 1 Kongresshaus: Meeting Venue
- 2 Zürich Hauptbahnhof: Main Train Station
- 3 Bellevueplatz: Friday Evening Conference Dinner
- 4 Zürich Bürkliplatz: Thursday Excursion Boat Pick-up
- 5 Zunfthaus Zur Meisen: Networking Reception
- 6 Ascot Hotel ★★★★★
- 7 Best Western Premier Hotel Glockenhof ★★★★★
- 8 Hotel Baur au Lac ★★★★★
- 9 Hotel Park Hyatt Zürich ★★★★★
- 10 Hotel Rössli ★★★
- 11 Hotel Seehof ★★★
- 12 Sheraton Neues Schloss Hotel Zürich ★★★★★
- 13 Steigenberger Hotel Bellerive au Lac ★★★★★
- 14 Zürich Marriott ★★★★★

Networking Reception at Zunfthaus zur Meisen

This elegant late Baroque palace was built in the 18th century as the guild house of wine merchants. The house now contains a collection of 18th-century faience and porcelain. While the collection features some exquisite pieces by leading European porcelain manufacturers, including Meissen and Sevres, some of the most interesting exhibits are locally made items produced by Schooren and other Swiss manufacturers.



Commercial Exhibition

There will be an extensive commercial exhibition in the Hall at the Kongresshaus Zürich which will be open during the meeting starting on Thursday 4 September 2014.

Opening times:

Thursday 4 September 08:00–15:30


Friday 5 September 08:00–19:00

Saturday 6 September 08:00–16:00

Scientific Programme

All questions concerning the Scientific Programme should be addressed to the Club Jules Gonin Secretariat:

www.clubjulesgonin.com or
info@clubjulesgonin.com



How to get around in Zürich

The city of Zürich is not huge and most destinations in the center of town can be reached comfortably by foot within 20-30 minutes.

If you would like to go further afield there is a very well developed public transport system with trams, bus and trains. More information on-line: www.zvv.ch/en/

The Zürich CARD

The Zürich CARD offers you discounts on numerous activities in Zürich and its region. It is available for the period of 24 or 72 hours.



The Zürich CARD offers the following range of benefits:

- Free use of all public transportation in the city of Zürich and its region
- Free admission to most museums in Zürich
- 10% discount in many Zürich shops
- Culinary surprise in selected Zürich restaurants
- Reduced prices for city tours from Zürich Tourism
- Discounts on various cultural and leisure activities

Price for the ZürichCARD for 24 hours:
CHF 24.00

Purchase the card on-line or at the Zürich Tourist Office located in the main train station

More information: www.zuerich.com/en/Visitor/zuerich-card.html

Telephone: +41 (0) 44 215 40 00

Accompanying Persons Tours

Zürich City Walking Tour

Thursday 4 September, 09:30 to 12:30


Explore Zürich on a guided walking tour. We will show you the Lake area, the famous shopping street Bahnhofstrasse, Paradeplatz the financial heart of Zürich, and the pedestrian area of the Old Town. We also include a visit to the Lindenhof, which overlooks the historical Limmatquai, and which holds the key of the history of Zürich's birthplace.



St. Gallen Baroque UNESCO Heritage Site, Cheese Factory with Cheese Tasting


Friday 5 September, 09:00 to 17:00

This most interesting excursion will take us to St. Gallen where we visit the Baroque cathedral with the Abbey Library, which houses some 160,000 documents – in part hand-written and over a thousand years old. The library probably boasts Switzerland's most beautiful Rococo hall and the entire Abbey precinct was declared an UNESCO world heritage site in 1983. By coach we continue to the green and hilly region of Appenzell, where we will have lunch. A pleasant stroll through the car-free village of Appenzell will take us through its pretty lanes with beautifully decorated facades of the old traditional buildings. In the afternoon we continue to the cheese factory where the famous Appenzeller cheese is made! On a guided tour we learn more about the cheese making techniques and the ancient traditions of this typical region. Return to Zürich in the late afternoon.



Pre- and Post-Meeting Tours

Pre- and post meeting tours can be arranged through the Zürich Tourist Office (www.zuerich.ch). The staff at the registration desk at the Kongresshaus will help you in the choice of tours and in the organisation.



Scientific Programme

Audiovisual Requirements

Presentations should be submitted in Powerpoint or Keynote format. To avoid any cross platform issues, Windows powerpoint files will be replayed on a windows machine and Macintosh powerpoint files on a Mac. Keynote files will be replayed on a Mac running Keynote. Presentations may be submitted on CD-ROMs or USB memory sticks. When preparing videos, ensure that they are saved in a 'standard' form without the use of unusual file formats or codecs (which may not be available on the presentation machines). The following formats are recommended: .avi and .mov Windows: Files playable on Windows Media Player, Macintosh: Files playable on Quicktime.

When embedding videos in a presentation, remember that by default, the video is NOT saved as part of the presentation, but rather a link to where it is saved. Therefore the video file must be included along with the powerpoint or keynote file. Once the files have been transferred to the presentation machine, the link may 'break', requiring the re-insertion of the video in the presentation. This should be tested in the ready room.

The fonts, which are used in the presentations, should be "Latin-based fonts". If the speaker needs special fonts, they should be stored as "embedded fonts" with the presentation (File -> save as "name of presentation" and under "tools" -> save options mark the checkbox "embed True type fonts" and select "embed all characters"). When using mathematical symbols please use those, which are available under Latin fonts (Unicode or DOS: Western Europe).

Time allocations for oral presentations

Please note that the times allocated for the different types of presentations are the following: Full paper: 8 minutes plus 2 minutes discussion, Rapid Fire paper: 3 minutes plus 2 minutes discussion, Fluorescein conference case: 3 minutes plus 3 minutes discussion.

Speaker Ready Room

The speaker ready room is located at the same level as the entrance hall. Please follow the sign posts. Both PC and Apple Macintosh computers will be available for speakers to check their powerpoint or keynote presentations prior to their presentation. Presentations should be submitted to the Speaker Ready Desk at least 1 hour before the start of the session. First speakers in the morning are requested to submit their presentations the evening before.

Opening times:

Wednesday 3 September	14:00 – 19:00
Thursday 4 September	07:30 – 15:30
Friday 5 September	07:30 – 18:00
Saturday 6 September	07:30 – 16:00

Poster Presentations

Posters should be placed on panels in the exhibition area on Wednesday 3 September and removed on Saturday afternoon 6 September after the meeting. The Poster Session with refreshments will be held within the poster/exhibition area on Friday 5 September. Poster authors should be present in person during the whole session to discuss their work.

- The size of poster panel is height 150cm x width 120cm.
- The title, authors and affiliations should be included in the poster.
- Your poster size is to be height 120cm x width 85cm, portrait A0.

Please use velcro to place your poster onto the panel. Velcro will be provided by the Secretariat.

Internet Access

Wireless internet will be provided complimentary to all participants, in all official meeting space.

Synopsis of Scientific Programme

WEDNESDAY, 3 SEPTEMBER 2014

14:00-15:00	INDUSTRY SYMPOSIUM
15:00-16:00	INDUSTRY SYMPOSIUM
16:00-17:00	INDUSTRY SYMPOSIUM
17:00-19:00	FLUORESCENCE CONFERENCE
19:30-21:00	NETWORKING RECEPTION



THURSDAY, 4 SEPTEMBER 2014

08:00	OPENING OF MEETING
08:00-09:50	SESSION I AGE RELATED MACULAR DEGENERATION
09:50-10:20	BREAK
10:20-11:50	SESSION II RETINAL IMAGING
11:50-13:00	SESSION III RAPID FIRE PAPERS: ARMD-RETINAL IMAGING
13:00-14:00	LUNCH
14:00-15:00	SESSION IV VITREO-RETINAL SURGERY
15:45-22:00	EXCURSION DINNER AT RAPPERSWILL CASTLE

FRIDAY, 5 SEPTEMBER 2014

07:30-08:15	GONIN BUSINESS MEETING
08:30-10:00	AWARD SESSION HERMANN WACKER LECTURE: CLAUS ECKARDT JULES GONIN LECTURE: FRANK G. HOLZ YASUO TANO LECTURE: GEORGE A. WILLIAMS GRAGOUHAS AWARD: JOHANNES VAN DE VEN

10:00-10:30	BREAK
10:30-11:30	SESSION V TUMORS
11:30-12:15	SESSION VI RAPID FIRE PAPERS: TUMORS
12:15-13:30	LUNCH
13:30-15:00	SESSION VII VITREO-RETINAL SURGERY
15:00-15:30	BREAK
15:30-17:30	SESSION VIII DIABETIC RETINOPATHY AND VASCULAR DISEASES
17:30-18:45	SESSION IX POSTER SESSION
19:30-22:00	CONFERENCE DINNER

SATURDAY, 6 SEPTEMBER 2014

08:00-08:30	SESSION X DIABETIC RETINOPATHY AND VASCULAR DISEASES
08:30-08:55	SESSION XI RAPID FIRE PAPERS: DIABETIC RETINOPATHY AND VASCULAR DISEASES
08:55-09:45	SESSION XII PEDIATRIC RETINA DYSTROPHIES
09:45-10:15	BREAK
10:15-11:15	SESSION XIII VITREO-RETINAL SURGERY
11:15-12:15	SESSION XIV RAPID FIRE PAPERS: VITREO-RETINAL SURGERY
12:15-13:30	LUNCH
13:30-14:10	SESSION XV INFLAMMATION/ENDOPHTHALMITIS
14:10-14:30	SESSION XVI RAPID FIRE PAPERS: PEDIATRIC- INFLAMMATION
14:30-15:00	SESSION XVII RAPID FIRE PAPERS: CLINICAL STUDIES
15:00-15:20	BREAK
15:20-17:00	SESSION XVIII CLINICAL STUDIES
	END OF MEETING

SCIENTIFIC PROGRAMME

THURSDAY, 4 SEPTEMBER 2014

08:00 OPENING OF MEETING

08:00-09:50 SESSION I

AGE RELATED MACULAR DEGENERATION

- 1** TOWARD A GLOBAL ATLAS OF AMD
A.F. Cruess, K. Gordon, A. Gordoio
- 2** PHARMACODYNAMIC AND PHARMACOKINETIC PROFILE OF INTRAOCULAR AFLIBERCEPT (EYLEA) IN PATIENTS WITH NEOVASCULAR AMD RECEIVING INTRAVITREAL AFLIBERCEPT THERAPY
C.H. Meyer, T.U. Krohne, Z. Liu, C.K. Chan
- 3** SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR CONCENTRATIONS BEFORE AND AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION
M. Ohji, X. Wang, T. Sawada
- 4** PROGNOSTIC PARAMETERS RELEVANT TO GUIDE ANTI-VEGF THERAPY IN NEOVASCULAR AMD
U. Schmidt-Erfurth, S. Waldstein, M. Kundi, C. Simader
- 5** HUMAN EMBRYONIC STEM CELL DERIVED RETINAL PIGMENT EPITHELIAL TRANSPLANTATION TRIALS IN PATIENTS WITH MACULAR DEGENERATIONS: LONG-TERM PHASE 1-2 SAFETY RESULTS
S.D. Schwartz, C.D. Regillo, D. Elliott, B. Lam, P. Rosenfeld, N. Gregori, J. Bainbridge, J.P. Hubschman, G. Heilweil, E. Anglade, R. Lanza
- 6** THE RAAV.SFLT-1 PHASE I GENE THERAPY TRIAL FOR EXUDATIVE AGE- RELATED MACULAR DEGENERATION: ONE YEAR FOLLOW-UP
M. Blumenkranz, I. Constable, P. Rakoczy, C. Lai, S. Schwartz, T. Chalberg
- 7** MACULAR MORPHOLOGY AND VISUAL ACUITY IN THE SECOND YEAR OF THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS (CATT)
G.J. Jaffe, S. Sharma, C.A. Toth, E. Daniel, J.E. Grunwald, M.G. Maguire, G.S. Ying, D.F. Martin
- 8** RANIBIZUMAB VERSUS BEVACIZUMAB FOR NEOVASCULAR AGE- RELATED MACULAR DEGENERATION. RESULTS FROM THE GEFAL NONINFERIORITY RANDOMIZED TRIAL AND AN UPDATED META- ANALYSIS OF RANDOMISED CLINICAL TRIALS
L. Kodjikian, E.H. Souied, G. Mimoun, M. Mauget-Faysse, F. Behar-Cohen, E. Decullier, L. Huot
- 9** MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
R.F. Spaide, T. Sato, M. Suzuki, S. Ooto
- 10** THE MAHALO PHASE II RESULTS: LAMPALIZUMAB (ANTI-FACTOR D) IN PATIENTS WITH GEOGRAPHIC ATROPHY
F.G. Holz, S. Schmitz-Valckenberg, B.L. Yaspan, Z. Li, A. Dressen, M. van Lookeren Campagne, R. Graham, T. Beres, K. Le, E. Henry, C. Ho, E.C. Strauss on behalf of the MAHALO Study Investigators

- 11** COMBINATION THERAPY OF INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR AND RANIBIZUMAB FOR TYPE 2 CHOROIDAL NEOVASCULARIZATION: A PILOT STUDY
T. Yasukawa, Y. Ogura

09:50-10:20 BREAK

10:20-11:50 SESSION II RETINAL IMAGING

- 12** INTERNATIONAL TELEMEDICINE IN VITREORETINAL DISORDERS
A. Yoshida, S. Ishiko, H. Hayashi, A. Takahashi, H. Hirokawa
- 13** DISTRIBUTION OF CHOROIDAL THICKNESS IN HEALTHY SUBJECTS MEASURED BY OPTICAL COHERENCE TOMOGRAPHY (OCT)
N.E. Bechrakis, C. Vollmuth, G. Haas, G. Blatsios
- 14** ULTRASOUND IMAGING AND CHARACTERIZATION OF CHOROIDAL PERFUSION
D.J. Coleman, R.H. Silverman, H.O. Lloyd, S. Daly
- 15** INTRASURGICAL OPTICAL COHERENCE TOMOGRAPHY WITH SMALL GAUGE FIBER OPTICS
H. Terasaki, T. Asami, Y. Ito, T. Sugita, J. Nishiyama, M. Kobayashi, N. Nishizawa
- 16** CHOROIDAL THICKENING WITH IMPAIRED CIRCULATION IN ACUTE IDIOPATHIC MACULOPATHY
S. Ishida
- 17** FEASIBILITY AND CLINICAL UTILITY OF ULTRA-WIDEFIELD INDOCYANINE GREEN ANGIOGRAPHY
S. Kiss, M.A. Klufas, N.A. Yannuzzi, C.E. Pang, S. Srinivas, S.V.R. Sadda, K.B. Freund
- 18** LONGITUDINAL LONG-TERM STUDY OF PROGRESSION OF ARM TO ARM IN PATIENTS WITH HIGH VS. LOW DENSITY OF MACULAR PIGMENT
U.E.K. Wolf-Schnurrbusch, S.P. Rothenbühler, V. Enzmann, A. Zenger, S. Wolf
- 19** MORPHOLOGICAL AND CLINICAL FINDINGS IN PATIENTS WITH CAVITARY OPTIC DISC ANOMALIES
L.M. Jampol, J. Fingert, M.R. Munk
- 20** RETINAL OXYGEN METABOLISM IS ABNORMAL IN DIABETIC RETINOPATHY, AMD, RETINAL VASCULAR OCCLUSIONS, RETINITIS PIGMENTOSA AND GLAUCOMA
E. Stefánsson, S.H. Hardarson, A. Geirsdottir, O.B. Olafsdottir, J.V. Kristjansdottir, T. Scheving, T. Eysteinnsson

11:50-13:00 SESSION III

RAPID FIRE PAPERS: ARMD-RETINAL IMAGING

- 21** PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION: LONG-TERM MORPHOLOGICAL AND FUNCTIONAL OUTCOME IN THE NATURAL HISTORY FAM-STUDY
S. Schmitz-Valckenberg, M. Fleckenstein, M. Lindner, A.P. Göbel, F.G. Holz on behalf of the FAM-Study Group

- 22** THE PERIPHERAL RETINA IN AGE RELATED MACULAR DEGENERATION: IS IT RELEVANT? RESULTS FROM THE INTERNATIONAL OPERA STUDY
T.R. Friberg, G. Bencic, Z. Vatavuk, B. Andrijevic Derk, M. Zoric-Geber, T. Knezevic, V. Jurisic Friberg
- 23** VASCULAR ENDOTHELIAL GROWTH FACTOR SUPPRESSION TIME UNDER AFLIBERCEPT TREATMENT IN AGE-RELATED MACULAR DEGENERATION
S. Fauser, V. Schwabecker, B. Kirchhof, P.S. Muether
- 24** LONG-TERM ANTI-VEGF THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: PROGNOSTIC FACTORS, TREATMENT BENEFIT, AND OUTCOME
J.W. Miller, M. Braschler Simeonova, M. Roh, T. Braschler, D.G. Vavvas, I.K. Kim
- 25** VERTEPORFIN PHOTODYNAMIC THERAPY COMBINED WITH RANIBIZUMAB INTRAVITREOUS PHARMACOTHERAPY FOR TREATMENT- NAÏVE POLYPOIDAL CHOROIDAL VASCULOPATHY. TWO-YEAR RESULTS
A.N. Stangos, G.S. Figueiredo, S.P. Harding, J. Nair-Sahni
- 26** AUTOPHAGY IN THE RETINAL PIGMENT EPITHELIUM: INSIGHTS INTO AGE- RELATED MACULAR DEGENERATION
D.N. Zacks, J. Yao, L. Jia, D.A. Thompson, J.L. Dunaief, M. Boulton
- 27** FLUORESCENCE LIFETIME CHARACTERISTICS IN STARGARDT'S DISEASE AND IN PSEUDOVITELLIFORM MACULAR DYSTROPHY
S. Wolf, C. Dysli, J.R. Sparrow, M. Zinkernagel
- 28** COMPARISON OF DISTANCE AND NEAR VISION IN THE BETTER-SEEING EYE VS. BOTH EYES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
N.M. Bressler, L.N. Chen, V. Chaikitmongkol, A.S. Wenick, S.B. Bressler
- 29** ROLE OF PDGF ANTAGONISM AND DEVELOPMENT OF SUBRETINAL FIBROSIS IN A PHASE 2, RANDOMIZED, DOUBLE MASKED, CONTROLLED TRIAL OF INTRAVITREOUS INJECTIONS OF FOVISTA™ (ANTI-PDGF PEGYLATED APTAMER) ADMINISTE
J.A. Wells
- 30** THE HOME STUDY: HOME MONITORING OF INTERMEDIATE AMD PATIENTS
S.B. Bressler for the Age-Related Eye Disease Study 2 (AREDS2) - HOME Study Group
- 31** THE SYSTEMIC ABSORPTION OF BEVACIZUMAB AND RANIBIZUMAB IN DME
S. Sharma, D. Johnson, M. Yat Tse, A. Brissette, D. Almeida, E. Moss, S.C. Pang, M. Al-Malki
- 32** RANIBIZUMAB TREATMENT FOR VISUAL IMPAIRMENT DUE TO MYOPIC CHOROIDAL NEOVASCULARIZATION: A SUB-GROUP ANALYSIS OF THE RADIANCE STUDY BY PATIENT BASELINE CHARACTERISTICS
T. Y. Wong
- 33** THE THERAPEUTIC RESPONSE OF RANIBIZUMAB AND AFLIBERCEPT DURING THE FIRST SIX MONTHS OF TREATMENT FOR EXUDATIVE AGE RELATED MACULAR DEGENERATION
M. Zinkernagel, A. Ebnetter, S. Wolf

- 34** IN-VIVO MULTIMODAL IMAGING OF EMULSIFIED RETAINED SILICONE OIL CRYOGENIC TRANSMISSION ELECTRON MICROSCOPY OF EXTRACTED 'NON-EMULSIFIED' INTRAVITREAL SILICONE OIL
Y. Fisher, J. McCann

13:00-14:00 LUNCH

**14:00-15:00 SESSION IV
VITREO-RETINAL SURGERY**

- 35** STAINING ASSISTED-SILICON OIL REMOVAL (ST-ROSO) FOR THE PREVENTION OF SUBLINICAL PROLIFERATIVE VITREORETINOPATHY (PVR)
S. Rizzo, F. Faraldi, F. Barca, T. Caporossi
- 36** OZURDEX IMPLANTS IN SILICONE OIL FILLED EYES
D.G. Charteris, P. Petrou, P. Banerjee
- 37** DEFERRAL OF SURGERY FOR PATIENTS WITH ERM AND GOOD VISUAL ACUITY IS SAFE
M. la Cour, M. Kofod
- 38** SUPRACHOROIDAL HYDROGEL IMPLANTS – A NEW TECHNIQUE FOR RETINAL DETACHMENT SURGERY
P. Szurman
- 39** VITRECTOMY AND SCLERAL SHORTENING IN PATIENTS WITH MACULAR HOLE RETINAL DETACHMENT OR MYOPIC TRACTION MACULOPATHY
A. Hirakata, Y. Ando, R. Yokota, T. Orihara, D. Kunita, K. Hirota, T. Koto, M. Inoue
- 40** OUTCOME OF COMPLEX RETINAL DETACHMENT SURGERY AFTER REMOVAL OF SILICONE OIL TAMPONADE
A. Wolf, A. Kampik

**15:45-22:00 EXCURSION
DINNER AT RAPPERSWILL CASTLE**

FRIDAY, 5 SEPTEMBER 2014

07:30-08:15 GONIN BUSINESS MEETING

08:30-10:00 AWARD SESSION

HERMANN WACKER LECTURE: Claus Eckardt

JULES GONIN LECTURE: Frank G. Holz

YASUO TANO LECTURE: George A. Williams

GRAGODAS AWARD: Johannes Van De Ven

10:00-10:30 BREAK

10:30-11:30 SESSION V TUMORS

- 41** ENDORESECTION TECHNIQUE FOR MANAGEMENT OF HIGH POSTERIOR CHOROIDAL MELANOMA: EXTENDED FOLLOW-UP RESULTS
J. Garcia-Arumi, M. Zapata, M. Leila, A. Boixadera, V. Martinez-Castillo, B. Corcostegui
- 42** LONG TERM RESULTS IN EYE SALVAGING TREATMENT OF LARGE UVEAL MELANOMAS: TRANSRETINAL ENDORESECTION VS. BRACHYTHERAPY
N. Bornfeld, M. Freistühler, E. Biewald, M. Gök, W. Sauerwein, G. Horstmann
- 43** INFLUENCE OF A GIANT RPE TEAR ON THE EVOLUTION OF DOME-SHAPED CHOROIDAL MELANOMAS AFTER PROTON BEAM RADIOTHERAPY
L. Zografos, A. Schalenbourg

- 44** CLINICAL CHARACTERISTICS OF UVEAL MELANOMA IN PATIENTS WITH GERMLINE BAP1 MUTATIONS
I.K. Kim, M. Patel, M.M. DeAngelis, K. Mayne, A.M. Lane, E.S. Gragoudas
- 45** INTRAVITREAL RABINIZUMAB FOR SECONDARY NEOVASCULARIZATION IN RETINOBLASTOMA AFTER INTRA-ARTERIAL CHEMOTHERAPY OR EXTERNAL BEAM IRRADIATION
F.L. Munier, M.C. Gaillard, S. Houghton, A. Balmer, M. Beck-Popovic
- 46** CHANGING TRENDS IN INITIAL MANAGEMENT OF UNILATERAL AND BILATERAL RETINOBLASTOMA SINCE 1900
J.J. Augsburger, Z.M. Corrêa
- 11:30-12:15 SESSION VI
RAPID FIRE PAPERS: TUMORS**
- 47** PHOTODYNAMIC THERAPY FOR RETINAL VASOPROLIFERATIVE TUMOUR
H. Heimann, F. Jmor, B. Damato
- 48** CAN WE TRUST THE BIOPSY FOR PROGNOSTICATION IN PATIENTS WITH CHOROIDAL MALIGNANT MELANOMAS?
J.F. Kiilgaard, M. Bagger, M.T. Andersen, S. Heegaard, M.K. Andersen
- 49** SINGLE INSTITUTION EXPERIENCE WITH FINE NEEDLE ASPIRATION BIOPSY (FNAB) AND GENE EXPRESSION PROFILE (GEP) OF POSTERIOR UVEAL MELANOMAS
Z.M. Corrêa, J.J. Augsburger
- 50** STEREOTACTIC RADIATION THERAPY OF DIFFUSE CHOROIDAL HEMANGIOMA IN STURGE-WEBER SYNDROME
A. Schalenbourg, L. Zografos, A. Pica
- 51** MICROINCISIONAL VITRECTOMY SURGERY FOR GENOMIC EVALUATION AND TREATMENT OF SMALL UVEAL MELANOMA/ATYPICAL CHOROIDAL NEVI
T.G. Murray, V. Villegas, A. Gold, A. Wildner, F. Ehliès, A. Alattiff
- 52** OCT HYPERREFLECTIVE INTRARETINAL SPOTS IN RADIATION MACULOPATHY
E. Midena, L. Frizziero, G. Midena, S. Vujosevic, E. Pilotto, R. Parrozzani
- 53** ASSOCIATION OF CLINICAL RISK FACTORS TO TIME OF METASTASIS IN PATIENTS WITH UVEAL MELANOMA
E.S. Gragoudas, A.M. Lane, I.K. Kim
- 54** ELECTRONIC FUNDUS TUMOR DRAWING USING A NOVEL TEMPLATE WITH AN IPAD
B. Damato, I. Respond-Kubiak
- 55** RISK OF SECONDARY ENUCLEATION AFTER HIGH VS LOW DOSE RATE RUTHENIUM BRACHYTHERAPY FOR UVEAL MELANOMA
S. Seregard, M. Lundell, G. Lundell, M. Fili
- 12:15-13:30 LUNCH**
- 13:30-15:00 SESSION VII VITREO-RETINAL SURGERY**
- 56** VITREOMACULAR INTERFACE IN A FRENCH POPULATION-BASED STUDY (THE MONTRACHET STUDY: MACULOPATHY, OPTICNERVE, NUTRITION, NEUROVASCULAR AND HEART DISEASES)
C. Creuzot-Garcher, J. Bouche-Pillon, P. Koehrer, C. Binquet, A. Bron
- 57** FOVEAL DETACHMENT AFTER IDIOPATHIC MACULAR HOLE SURGERY
R. Tadayoni, E. Boulanger-Scemama, A. Couturier, R. Hage, A. Gaudric, P. Massin
- 58** RESCAN 700. EXPERIENCE WITH A NEW, AVAILABLE, FULLY MICROSCOPE INTEGRATED OPTICAL COHERENCE TOMOGRAPH
S. Binder, C.I. Falkner-Radler, F. Zeiler, C. Ginzel, C. Glittenberg
- 59** SUBRETINAL AIR DISPLACEMENT OF SUBMACULAR HEMORRHAGE: INITIAL EXPERIENCE
T.H. Mahmoud, P.N. Dayani, C. Stone, J.E. Kim, M.D. Ober
- 60** A RESCUE THERAPY FOR PERSISTENT OPTIC DISC PIT MACULOPATHY IN PREVIOUSLY VITRECTOMIZED EYES
M.S. Figueroa, I. Contreras
- 61** DO WE NEED AN ADDITIONAL ENCIRCLING BAND FOR VITRECTOMY TO TREAT PSEUDOPHAKIC RETINAL DETACHMENT ? RESULTS FROM THE VIPER STUDY
P. Walter, S. Baumgarten, A. Pielen, B. Mazinani and the VIPER Study Group
- 62** INVERTED OR FREE INTERNAL LIMITING MEMBRANE FLAP COMBINED WITH AUTO-BLOOD CLOT FOR THE TREATMENT OF MACULAR HOLE RETINAL DETACHMENT IN HIGHLY MYOPIC EYES
C.C. Lai, L.H. Chuang, Y.P. Chen, N.K. Wang, L. Liu, Y.S. Hwang, K.J. Chen, W.C. Wu
- 63** SCLERAL BUCKLING FOR RECURRENT RETINAL DETACHMENT IN HIGHLY MYOPIC EYES
G. Ripandelli, M. Stirpe
- 64** ADVANCES IN VITREORETINAL SURGERY IN ASSOCIATION WITH PERMANENT KERATOPROSTHESIS
D.J. D'Amico, S. Kiss
- 15:00-15:30 BREAK**
- 15:30-17:30 SESSION VIII
DIABETIC RETINOPATHY AND VASCULAR DISEASES**
- 65** EFFECT OF DOXYCYCLINE VERSUS PLACEBO ON RETINAL FUNCTION AND DIABETIC RETINOPATHY PROGRESSION IN PATIENTS WITH SEVERE NONPROLIFERATIVE OR NON-HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY
I.U. Scott, G.R. Jackson, D.A. Quillen, M. Larsen, R. Klein, J. Liao, S. Holfort, I.C. Munch, T.W. Gardner
- 66** ARTERIOVENOUS NICKINGS: A REAPPRAISAL
M. Paques, A. Brolly, E. Koch, F. Rossant
- 67** COMPARISON OF VISUAL AND OCT OUTCOMES IN EYES WITH AND WITHOUT PRIOR VITRECTOMY RECEIVING ANTI-VEGF THERAPY IN A RANDOMIZED TRIAL ON RANIBIZUMAB PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA
C.K. Chan for the Diabetic Retinopathy Clinical Research Network
- 68** LONG-TERM SURVIVAL RATES OF PATIENTS UNDERGOING VITREOUS SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY
L. Wickham, P.J. Banerjee, R. Moya, C. Bunce, D.G. Charteris, D. Yorston

- 69** MACULAR ISCHEMIA AND OUTCOME OF VITRECTOMY FOR DIABETIC MACULAR EDEMA
S.W. Kang, H. Chung, J. Kim, G.E. Cho
- 70** MECHANISMS OF VISUAL FUNCTION LOSS IN PROLIFERATIVE DIABETIC RETINOPATHY
T.W. Gardner, G.E. Boynton, M.S. Stem, L. Kwark, S. Farsi, G.R. Jackson
- 71** ADMIXTURE GENETIC MAPPING FOR DIABETIC RETINOPATHY GENES IN AFRICAN AMERICANS
L. Sobrin, A. Penman, A. Tandon, H. Hancock, M. James, D. Husain, C. Andreoli, O. Idowu, D. Riche, S. Brauner, S.O. Smith, S. Hoadley, C. Richardson, V. Vazquez, C. Chi, R. Jensen, M.F. Cotch, D. Siscovick, H.A. Taylor, J.G. Wilson, D. Reich, T.Y. Wong, R. Klein, B.E.K. Klein, J. I. Rotter, N. Patterson, C. J. Chen
- 72** LONG TERM ANALYSIS OF PATIENTS TREATED WITH COMBINATION THERAPY USING ANTI-VEGF THERAPY AND DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX) FOR RETINAL VEIN OCCLUSION
M. Singer, P. Woods, D. Bell, J. Esplitia, T. Kreitz
- 73** MACULAR MICROCYSTS AS EARLY PROGNOSTIC FACTOR FOR RECURRENCE OF MACULAR EDEMA IN PATIENTS WITH RETINAL VEIN OCCLUSIONS
M. Rehak, M. Tuisl, P. Wiedemann
- 74** REGULATION OF CADHERIN 5 BY CORTICOSTEROIDS AND ASSOCIATION WITH CENTRAL SEROUS CHORIORETINOPATHY
M. Larsen, C. Schubert, A. Pryds, S. Zeng, K.B. Freund, R.F. Spaide, J.C. Merriam, I. Barbazetto, J.S. Slakter, S. Chang
- 75** MINERALOCORTICOID RECEPTORS IN THE RETINA: FROM BASIC UNDERSTANDING TO CLINICAL APPLICATIONS
F. Behar-Cohen, M. Zhao, F. Jaisser, E. Bousquet, N. Farman
- 76** RESTORING VISION: FROM PROSTHESIS TO OPTOGENETICS
J.A. Sahel, D. Dalkara, S. Picaud
- 17:30-18:45** **SESSION IX**
POSTER SESSION
- Age Related Macular Degeneration**
- P1** OUTER RETINAL TUBULATION IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB
I. Mantel, A. Dirani, C. Gianniu, L. Marchionno, D. Decugis, A. Ambresin
- P2** DELAYED TYPE HYPERSENSITIVITY REACTION SECONDARY TO ANTIVEGF MAB INTRAVITREAL INJECTIONS
A. Ambresin, C. Gianniu, G. Buss, F. Spertini
- P3** LINEARITY OF GROWTH IN TIME IN GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION
J. Monés, M. Biarnés, H. Muhtaseb
- P4** CHOROIDAL NEOVASCULARIZATION IN EYES WITH CHOROIDAL VASCULAR HYPERPERMEABILITY
N. Yoshimura
- P5** CIRCULATING OMEGA-3 FATTY ACIDS AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
E.H. Souied, B. Merle, P. Benlian, N. Puche, C. Delcourt
- P6** FIVE-YEAR RESULTS OF COMBINED TREATMENT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: VERTEPORFIN PDT AND INTRAVITREAL ANTI-VEGF
S.Y. Yu, T.K. Kim, H.W. Kwak
- P7** ADJUNCTIVE PHOTODYNAMIC THERAPY FOR TYPE 1 CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH THICKENED CHOROID AND REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY
W.K. Lee, H. Chung
- P8** SUBFOVEAL CHOROIDAL THICKNESS CHANGES AFTER INTRAVITREAL RANIBIZUMAB AND PHOTODYNAMIC THERAPY IN RETINAL ANGIOMATOUS PROLIFERATION
T. Iida, I. Maruko
- P9** LONGITUDINAL STRUCTURE FUNCTION ANALYSIS IN RETICULAR PSEUDODRUSEN
N. Eter, C. Clemens, P. Heiduschka, F. Alten
- P10** CHANGES IN VISUAL ACUITY IN PATIENTS WITH CHOROIDAL NEOVASCULARISATION IN ANGIOID STREAKS TREATED BY AFLIBERCEPT INTRAVITREAL INJECTIONS
G. Mimoun, J. Tilleul, E.H. Souied
- Retinal Imaging**
- P11** CHOROIDAL THICKNESS IN CHILDREN MEASURED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
I. Pinilla, L. X. Herrera, D. Perez-Garcia, I. Perez-Navarro, J. Ibañez, A. Sanchez-Cano, E. Abecia
- P12** IMAGING OF MACULAR HOLES USING ADAPTIVE OPTICS
M. Saleh, G. Debellemanni, A. Koehl, B. Delbosc
- P13** VISUALIZATION QUALITY ENHANCEMENT OF SURGICAL MICROSCOPE MOUNTED INTRA-SURGICAL OCT DATA USING CUDA BASED RENDERING C.
Glittenberg, S. Binder
- P14** CHANGES IN VISUAL PROGNOSIS OVER 5 YEARS OF WET AMD TREATMENT
H. Lund-Andersen, A. Rasmussen, S.B. Bloch, J. Fuchs, L.H. Hansen, M. Larsen, B. Sander
- P15** EN FACE REPRESENTATION OF THE STAGES OF POSTERIOR VITREOUS DETACHMENT (PVD) TO ENHANCE SURGICAL DECISION MAKING AND UNDERSTANDING OF VITREORETINAL INTERFACE DISEASES
B. Wolff
- Vitreoretinal Surgery**
- P16** SURGICAL TREATMENT FOR TERSON'S SYNDROME AND RATE IN SAB PATIENTS
L. Wagenfeld, P. Czorlich, J. Regelsberger, B. Stemplewitz, G. Richard, C. Skevas
- P17** VITRECTOMY AND SILICONE OIL WITH OR WITHOUT ENCIRCLING EPISCLERAL BAND IN THE MANAGEMENT OF GUN SHOT PERFORATING EYE INJURY (COMPARATIVE STUDY)
H. Ghoraba, M. Hiekal, H.O. Mansour, H.M. Abdelfattah, E.M. Elgemei, S.M. Elgouhary
- P18** VITRECTOMY VERSUS SCLERAL BUCKLING IN PHAKIC RHEGματοGENOUS UNCOMPLICATED RETINAL DETACHMENT: A RANDOMIZED STUDY
E. Abecia, A. Ferreras, I. Pinilla

- P19** SCANNING ELECTRON MICROSCOPY OF EPIRETINAL MACULAR MEMBRANES AND THEIR RELATIONSHIP WITH OCT AND VISUAL ACUITY
C. Azzolini, T. Congiu, S. Donati, M. Romano, S. Battistini, P. Basso
- P20** WHEN DOES SPONTANEOUS RESOLUTION OCCUR IN A VITREOMACULAR TRACTION GROUP?
F. Ziemssen, S. Dimopoulos, F. Gelissen, K. Januschowski, K.U. Bartz-Schmidt
- P21** INTRAOCULAR PRESSURE CHANGES IN PATIENTS WITH GAS-FILLED EYES DURING ASCENDING CAR TRAVEL
A. Assi, A. Dirani, A. Fadlallah, G. Cherfan
- P22** RETINAL RE-ATTACHMENT IN COMPLICATED RETINAL DETACHMENTS: HOW TO HANDLE SILICONE OIL PROPERLY
F. Koch, S. Deuchler, P. Singh, T. Kohnen, M. Müller
- P23** THE BEST USE OF TEMPERATURE AS A SURGICAL TOOL
M.R. Romano
- P24** A NEW SIMPLIFIED SURGICAL TECHNIQUE FOR ENCIRCLING SCLERAL BUCKLE SURGERY FOR PRIMARY RETINAL DETACHMENT
D.G. Vavvas, D. Skondra, T. Papakostas
- P25** FOVEAL AUTOFLUORESCENCE AND PHOTORECEPTORS INTEGRITY AFTER SUCCESSFUL RHEGMATOGENOUS RETINAL DETACHMENT REPAIR
F.J. Rodriguez, A.C. Brieke, H. Tovar
- P26** PREDISPOSING FACTORS AND PROGNOSIS OF POSTOPERATIVE FOVEAL DETACHMENT FOLLOWING SUCCESSFUL MACULAR HOLE (MH) SURGERY
P. Tranos, S. Asteriades, T. Vakalis
- P27** COMPARISON OF VITRECTOMY ALONE, VERSUS VITRECTOMY WITH SCLERAL BUCKLE FOR ADVANCED PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A RETROSPECTIVE REVIEW
O.N. Okonkwo, A.O. Hassan, O. Oderinlo
- P28** RHEGMATOGENOUS RETINAL DETACHMENT TRIGGERING A DRASTIC AUTOIMMUNE UVEITIS
A.L.H. Siam, T.A. El Maamoun
- P29** THE OUTCOME OF SECONDARY RETINECTOMIES FOR PVR
I. Immonen
- P30** ENDORESECTION OF OCULAR MELANOMA TO TREAT INTRACTABLE BLEEDING FROM MELANOMA AFTER RADIOTHERAPY
M.H. Goldbaum, H. Ferreyra
- P31** PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT –PREOPERATIVE STATUS, SURGICAL METHODS AND ANATOMICAL OUTCOME
R. Bragadóttir, M. Haugstad
- P32** COMPARATIVE OUTCOMES OF LONG-ACTING GAS AND SILICONE OIL TAMPONADES IN CASES WITH RHEGMATOGENOUS RETINAL DETACHMENT COMPLICATED BY SEVERE PROLIFERATIVE VITREORETINOPATHY
R. Avci, S. Yilmaz, B. Kaderli, U.U. Inan, H. Ozcetin
- P33** 27-GAUGE VITRECTOMY FOR MACULAR SURGERY
J.C. Zech, J.L. Leynaud, F. Rouberol

Tumors

- P34** A MODIFIED DUMMY PLAQUE FOR ACCURATE PLACEMENT OF RUTHENIUM-106 PLAQUES IN EPISCLERAL BRACHYTHERAPY
J. Krohn
- P35** EDI-OCT AND PREDICTIVE RISK FACTORS FOR MALIGNANT TRANSFORMATION OF CHOROIDAL NEVI
M.A. Blasi, M.M. Pagliara, F. Leonardi, A. Villano
- P36** TREATMENT OF JUXTAPAPILLARY RETINAL HAEMANGIOMA WITH INTRAOCULAR STRONTIUM RADIATION SOURCE
N. Eide, T. Bærlund, B. Rekstad, T. Nilsen
- P37** SENSITIVITY AND RESISTANCE OF UVEAL MELANOMA (UM) CELLS TO PKC INHIBITION: ROLE OF THE STEROID RECEPTOR COACTIVATOR (SRC)-3
V. Poulaki, S.A. Chew, B.W. O'Malley, N. Mitsiades

Diabetes and Vascular Diseases

- P38** A PILOT STUDY FOR THE SAFETY AND EFFICACY OF INTRAVITREAL METHOTREXATE FOR PROLIFERATIVE DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA
S. Androudi, A. Dastiridou, T. Kaogeropoulos, E. Tsironi, A. Bargiota, P. Brazitikos
- P39** CLEARANCE RATE OF RETINAL HEMORRHAGES FOLLOWING INTRAVITREAL DEXAMETHASONE IMPLANT IN EYES WITH BRANCH RETINAL VEIN OCCLUSION
O. Cekic, S.A. Turhan
- P40** EARLY MANAGEMENT OF CENTRAL RETINAL VEIN OCCLUSION: ETIOLOGIC OR SYMPTOMATIC TREATMENT?
A. Glacet-Bernard, O. Rostaqui, N. Massamba, C. Fardeau, J. Tilleul, N. Puche, F. Coscas, P. Le Hoang, G. Coscas, E. Souied
- P41** SWITCHING TO AFLIBERCEPT IN FREQUENTLY RECURRING MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSIONS
S. Michels, H. Fassnacht-Riederle, M. Becker, M.E. Farah
- P42** EARLY NEURAL RETINAL CHANGES DETECTED BY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN TYPE 2 DIABETES MELLITUS
E.B. Rodrigues, M. Urias, F.M. Penha, M.E. Farah

Pediatric Retina and Dystrophies

- P43** PHENOTYPIC VARIATIONS OF STARGARDT DISEASE KL
B.J. Klevering, N.M. Bax, S. Lambertus, C.B. Hoyng
- P44** SURGERY FOR STAGE 5 ROP: INTERVENING IN 'EARLY' STAGE 5
S.S. Gadkari, S. Kulkarni, M. Deshpande
- P45** INTRAOPERATIVE SD-OCT IN PEDIATRIC VITREORETINAL SURGERY
P. Dorta, A. Kychenthal
- P46** INFANTILE MICROPHTHALMOS-COLOBOMA ASSOCIATED RETINAL DETACHMENT
C.K. Patel

Inflammation/Endophthalmitis

- P47** COMPARISON OF THE FUNCTIONAL AND ANATOMIC EFFECTS OF INTERFERON- β AND METHOTREXATE ON SECONDARY MACULAR EDEMA IN THE TREATMENT OF INTERMEDIATE UVEITIS: RESULTS OF A RANDOMIZED CONTROLLED CLINICAL
M.D. Becker, E. Jakob, C. Springer, B. Dobner, U. Wiehler, P. Weimer, K. Rohrschneider, C. Fiehn, R. Max, B. Storch-Hagenlocher, F. Mackensen
- P48** IMPORTANCE OF MULTIMODAL IMAGING IN THE APPRAISAL OF TOXOPLASMIC RETINOCHOROIDITIS
M. Khairallah, R. Kahloun, N. Abroug, I. Ksiai, B. Jelliti, S. Ben Yahia
- P49** PROPHYLAXIS FOR ACUTE SCLERAL BUCKLE INFECTION USING 0.25% POVIDONEIODINE OCULAR SURFACE IRRIGATION DURING SURGERY
H.S. Shimada
- P50** OCULAR NEOVASCULARIZATION IN A LARGE COHORT OF PATIENTS WITH UVEITIS
N.A. Sabrosa, L.D.P. Cubillan, A. Hovakimyan, E.T. Cunningham

Experimental and Clinical Studies

- P51** EFFECTS OF AFLIBERCEPT, RANIBIZUMAB AND BEVACIZUMAB ON CELL VIABILITY, PHAGOCYTOSIS AND MITOCHONDRIAL BIOENERGETICS OF HUMAN RETINAL PIGMENT EPITHELIAL CELLS
S.J. Sheu, N.C. Liu, J.Y.H. Chan
- P52** IDENTIFICATION OF THE MOLECULAR COMPOSITION OF A CONDITIONED MEDIUM THAT FOSTERS RPE SURVIVAL ON AMD AND AGED BRUCH'S MEMBRANE
I.K. Sugino, Q. Sun, C. Springer, N. Cheewatrakoolpong, T. Liu, W. Chen, H. Li, M.A. Zarbin
- P53** COLLAGENS INVOLVED IN VITREO-RETINAL ADHESION
L.I. Los, B. Wullink, S.C. Bu, R.J. van der Worp, R. Kuijter, J.M.M. Hooymans
- P54** THE IMPACT OF FINANCIAL CRISIS ON CENTRAL SEROUS CHORIORETINOPATHY IN GREECE: IS THERE ANY CORRELATION?
P. Theodossiadis, I.P. Chatziralli, I. Datseri, M. Tsilimbaris, D. Alonistiotis, V. Xanthopoulou, A.A. Rouvas
- P55** COMPARISON OF ROBOTIC ASSISTED AB EXTERNO SUBRETINAL BLEB FORMATION TO MANUALLY PERFORMED SURGERY
M.D. de Smet, T. Meenink, M. Beelen, G. Naus, C. Sachs, S.H. Popma
- P56** A SILICONE VITREOUS IMPLANT TO TREAT CHRONIC OCULAR HYPOTONY: PRELIMINARY FEASIBILITY DATA
A.W.A. Weinberger, W. Bayoudh, M. Frentz, D. Carstesen, D. Klee, B. Dittrich, C. Gummersbach, N.F. Schrage, P. Walter
- P57** TGF- β 1 INDUCED EPITHELIAL-MESENCHYMAL TRANSITION IN RPE CELL IS MEDIATED BY TAK-1 ACTIVATION
A. Pollack, M. Goldberg, Z. Dvashi
- P58** OZURDEX AS AN EFFECTIVE TREATMENT OPTION FOR MACULAR EDEMA DUE TO IRVINE GASS SYNDROME
C. Haritoglou, A. Kampik
- P59** PRE-CLINICAL INVESTIGATION WITH ZALTRAP
M.E. Farah, J.R. de Oliveira Dias, E. Badaró Cardoso, E. Amorim Novais, C.H. Meyer, E.B. Rodrigues

- P60** RETINAL DETACHMENT: WHAT YOUR GRANNY TAUGHT YOU OR WHAT YOUR GRANNY GAVE YOU?
M.P. Snead, C. Spickett, C.J. Hammond, D. Hill, A. Prescott, G.S. Fincham, A.V. Poulson, A.M. McNinch, A.J. Richards

19:30-22:00 CONFERENCE DINNER

SATURDAY, 6 SEPTEMBER 2014

08:00-08:30 SESSION X**DIABETIC RETINOPATHY AND VASCULAR DISEASES**

- 77** DEVELOPMENT OF A SEMI-AUTOMATED ALGORITHM FOR THE DETECTION OF PERIFOVEAL CAPILLARY NETWORK
M.K. Tsilimbaris, Z. Kapsala, A. Pallikaris
- 78** DIFFERENT GENETIC POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENT PHENOTYPES OF NON-PROLIFERATIVE DIABETIC RETINOPATHY
J.G. Cunha-Vaz, C. Lobo, S. Nunes, M. Costa, L. Ribeiro, R. Bernardes, M.J. Simões, C. Egas, C. Faro
- 79** RELATIONSHIP BETWEEN VITREOUS LEVELS OF MATRIX METALLOPROTEINASES AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN PROLIFERATIVE DIABETIC RETINOPATHY
A.M. Abu El-Asrar, G. Mohammad, M.I. Nawaz, M.M. Siddiquei, K. Van den Eynde, A. Mousa, G. De Hertogh, G. Opdenakker

08:30-08:55 SESSION XI**RAPID FIRE PAPERS: DIABETIC RETINOPATHY AND VASCULAR DISEASES**

- 80** ANGIOGENIC AND INFLAMMATORY BIOMARKERS ASSOCIATED WITH NEOVASCULAR GLAUCOMA
J. Arroyo, K. Lashkari, K. Marra, K. Kovacs
- 81** VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA; BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS
H.W. Kwak
- 82** CHOROIDAL THICKNESS IN DIABETIC RETINOPATHY: THE INFLUENCE OF ANTIANGIOGENIC THERAPY
R. Silva, I. Lains, J. Figueira
- 83** NETRIN-4 AS A KEY PLAYER IN OCULAR NEOVASCULAR DISEASE
A.M. Joussen, S. Skosirsky, C. Nürnberg, A.K. Maier, N. Reichardt, M. Koch, O. Strauss
- 84** EVALUATION OF THE EFFICACY OF RANIBIZUMAB FOR DIABETIC MACULAR EDEMA IN REAL LIFE PRACTICE
P. Massin, R. Hage, M. Lsanharawi, B. Dupas, J. Jacob, A. Erginay

08:55-09:45 SESSION XII PEDIATRIC RETINA DYSTROPHIES

- 85** RETINOPATHY OF PREMATURITY: A VASCULAR DISEASE AND MORE
C. Toth, R. Maldonado, S. Freedman, A. Tong, L. Vajzovic, K. Gustafson, S. Farsiu

- 86** SMART SOFTWARE FOR ROP TELEMEDICINE SCREENING
M.T. Trese, K.A. Drenser, A. Capone Jr., C.H. Park, J.L. Federman
- 87** INTERGRADER AGREEMENT OF FLUORESCEIN ANGIOGRAPHY FINDINGS FOR RETINOPATHY OF PREMATURITY
R.V.P. Chan, M.A. Klufas, S.N. Patel, K.E. Jonas, M.A. Martinez-Castellanos, A.M. Berrocal, M.F. Chiang
- 88** DISEASE PROGRESSION IN PATIENTS WITH WNT PATHWAY MUTATIONS ASSOCIATED WITH FAMILIAL EXUDATIVE VITREORETINOPATHY
A. Capone Jr., A.R. Shah, A. Alfaran, E.D. Nudleman, K.A. Drenser, M.T. Trese
- 89** GENOTYPE- PHENOTYPE CORRELATION OF PATIENTS WITH WNT PATHWAY MUTATIONS ASSOCIATED WITH FAMILIAL EXUDATIVE VITREORETINOPATHY: A BASIS FOR GENETICALLY TAILORED MANAGEMENT
K.A. Drenser, E. Nudleman, A. Alfaran, A.R. Shah, A. Capone Jr., M.T. Trese

09:45-10:15 BREAK

**10:15-11:15 SESSION XIII
VITREO-RETINAL SURGERY**

- 90** POSTERIOR VITREOUS DETACHMENT IN VITRECTOMY FOR FLOATERS
S.Y. Lesnik Oberstein, H.M. Bijl, M. Mura
- 91** ANALYSIS OF EPIRETINAL MEMBRANES USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY (OCT)
W.E. Smiddy, A.E. Kuriyan, D. Cabrera DeBuc
- 92** CORRELATION BETWEEN SD-OCT FINDINGS AND VISUAL OUTCOME AFTER MACULA-OFF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT
V. Martínez-Castillo, D. Velázquez, J. García-Arumí, A. Boixadera
- 93** REDUCED REQUIREMENT OF POSITIONING AFTER VITRECTOMY FOR PRIMARY RETINAL DETACHMENT
M. Kamei, S. Sakimoto, N. Matsumura, H. Sakaguchi
- 94** AN EVALUATION OF POSITIONING PROTOCOLS IN THE TREATMENT OF FULL THICKNESS MACULAR HOLES
M. Alberti, M. la Cour
- 95** CONE IMPLICIT TIME AS A PREDICTOR FOR VISUAL OUTCOME IN MACULAR HOLE SURGERY
S. Andréasson, F. Ghosh

**11:15-12:15 SESSION XIV
RAPID FIRE PAPERS: VITREO-RETINAL SURGERY**

- 96** VISUAL LOSS UNDER SILICONE OIL
J. Roider, J. Tode, T. Oppermann, J. Hillenkamp
- 97** ACUTE SUBMACULAR HEMORRHAGE IN AMD: A CONTROLLED TRIAL COMPARING INJECTIONS ONLY VERSUS VITRECTOMY TO ADMINISTER TPA, GAS AND BEVACIZUMAB TO DISPLACE SUBMACULAR BLOOD
J. van Meurs, R. Wubbels, K. Vermeer, H. de Jong, E. van Zeeburg
- 98** AN IN-DEPTH ANALYSIS OF THE LONG-TERM COURSE OF RECOVERY AFTER MACULAR SURGERY
J. Hillenkamp, K. Purtskhvanidze, F. Treumer, O. Junge, J. Hedderich, J. Roider

- 99** EFFICACY AND SAFETY OF 27-GAUGE VITRECTOMY FOR VITREOUS OPACITIES
T.J. Wolfensberger, J.A. Pournaras, P. Mandal
- 100** VITRECTOMY TECHNIQUE FOR DIABETIC VITREO MACULAR TRACTION WITH IMPENDING MACULAR HOLE
S.M. Sheta
- 101** DOES ADDITIONAL VITRECTOMY PREVENT PSEUDOPHACIC RETINAL DETACHMENT IN HIGH MYOPIA?
P. Wiedemann, R.D. Hilgers
- 102** MEMBRANE BLUE DUAL STAINING IN MACULAR SURGERY
C.I. Falkner-Radler, S. Binder
- 103** MICROSTRUCTURAL RETINAL FINDINGS BY SPECTRAL DOMAIN OCT AFTER VITRECTOMY REPAIR OF RHEGMATOGENOUS RETINAL DETACHMENTS
R.S. Apte, G.N. Kumar, P.K. Rao
- 104** POSTOPERATIVE RESTORATION OF FOVEAL INNER RETINAL CONFIGURATION IN PATIENTS WITH EPIRETINAL MEMBRANE AND ABNORMALLY THICK INNER RETINA
Y.H. Yoon, H.S. Yang, J.T. Kim, S.G. Joe, J.Y. Lee
- 105** RETINAL REATTACHMENT WITHOUT TAMPONADE: PRELIMINARY FINDINGS FROM AN ANIMAL MODEL
W.J. Heriot
- 106** UN-EXPLAINED VISUAL LOSS AFTER REMOVAL OF SILICONE OIL, RESULTS OF THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP (PACORES)
J.A. Roca, L. Wu, F. Rodríguez, A. Alezzandrini, G. Alvira, R. Velez, H. Quiroz, J.F. Arévalo, M. Serrano, M. Berrocal, M. Fig
- 107** RE-ACCUMULATION OF MACULAR PIGMENT AFTER SUCCESSFUL MACULAR HOLE SUGERY
F. Bottoni, E. Zanzottera, A. Caimi, E. Carini, M. Cereda, M. Cigada, G. Staurengi

12:15-13:30 LUNCH

**13:30-14:10 SESSION XV
INFLAMMATION/ ENDOPHTHALMITIS**

- 108** INFLAMMATORY EPISODES AFTER INTRAVITREAL ANTI-VEGF THERAPY
D.G. Callanan, D.Y. Chong, P.D. Williams
- 109** ONE-YEAR OUTCOMES OF THE SAVE STUDY: SIROLIMUS AS A THERAPEUTIC APPROACH FOR UVEITIS
Q.D. Nguyen, M.A. Ibrahim, Y.J. Sepah, A. Watters, M. Bittencourt, E.M. Vigil, J. Naor, N. Shams, D.V. Do
- 110** PARAPROTEINEMIC MACULOPATHY
J.F. Arevalo, A.M. Mansour, J. Badal, R.S. Moorthy, G.K. Shah, H. Zegarra, J. Pulido, A. Charbaji, L. Amselem, A.J. Lavaque, A. Casella, B. Ahmad, J.G. Paschall, A. Caimi, G. Staurengi
- 111** CURVULARIA ENDOPHTHALMITIS 33-YEAR REVIEW, PROLONGED INFECTION DUE TO ORGANISM SEQUESTRATION
T.A. Albini, A.V. Rachitskaya, A.K. Reddy, D. Miller, J. Davis, H.W. Flynn, W. Smiddy, S. Dubovy

14:10-14:30 SESSION XVI**RAPID FIRE PAPERS: PEDIATRIC - INFLAMMATION**

- 112** ECHOGRAPHIC CHARACTERIZATION OF RETINO-CHOROIDAL COLOBOMAS DEFINES SURGICAL INDICATIONS AND OUTCOMES
A.M. Berrocal, V.D. Venincasa, Y.S. Modi, H.A. Aziz, W. Shi, T.G. Murray, H.W. Flynn Jr.
- 113** PHENOTYPE OF BIRDSHOT RETINOCHOROIDITIS IS MODIFIED BY EARLY AND SUSTAINED INFLAMMATION SUPPRESSIVE TREATMENT
C.P. Herborn, M. Papadia, P.B. Knecht
- 114** GENDER DIFFERENCES IN BIRDSHOT CHORIORETINOPATHY AND THE WHITE DOT SYNDROMES: DO THEY EXIST?
L.J. Faia, G.A. Williams
- 115** ANATOMICAL AND VISUAL OUTCOME AFTER PARS PLANA VITRECTOMY IN ACUTE POSTOPERATIVE BACTERIAL ENDOPHTHALMITIS IN PATIENTS UNDERGOING CATARACT SURGERY
C. Chiquet, F. Rouberol, G. Thuret, P.L. Cornut, K. Palombi, C. Creuzot-Garcher On behalf of the FRIENDS (French Institutional Endophthalmitis Study) group

14:30-15:00 SESSION XVII**RAPID FIRE PAPERS: CLINICAL STUDIES**

- 116** VITREOUS PROTEOMIC ANALYSIS: NEW MARKERS FOR VITREORETINAL DISEASES?
J.A. Pournaras, T.J. Wolfensberger, C. Salvisberg, C. Fouda, A. Hainard, N. Turck
- 117** SAFETY STRATEGIES IN TRANSPOSON-BASED PLASMIDS FOR GENE THERAPY
G. Thumann, C. Marie, Z. Izsvak, D. Scherman, N. Harmening, M. Kropp, S. Johnen
- 118** FAMILY HISTORY AS A RISK FACTOR FOR AGE-RELATED MACULAR DEGENERATION (AMD)
C.B. Hoyng, N.T.M. Saksens, S.K. Verbakel, J.M.M. Groenewoud, A.I. den Hollander, C.J.F. Boon
- 119** CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: LONG TERM FOLLOW-UP AND VISION-RELATED QUALITY OF LIFE
J.E.E. Keunen, C.B. Hoyng, A.J.M. Dingemans, M.B. Breukink, A.I. den Hollander, S.M. Downes, C.J.F. Boon
- 120** TESTING THE RETINAL EFFECTS OF THE NOVEL DYE ACID VIOLET-17 FOR AN INTRAOCULAR APPLICATION IN VITREO-RETINAL SURGERY
A. Tura, A. Alt, C. Haritoglou, C.H. Meyer, T. Schneider, S. Grisanti, J. Lüke, M. Lüke for the International Chromovitrectomy Collaboration
- 121** RELATIONSHIP BETWEEN CHOROIDAL THICKNESS AND CHOROIDAL CIRCULATION IN HEALTHY YOUNG SUBJECTS
C.J. Pournaras, G. Donati, E. Frountzou, M. Geiser, C.E. Riva

15:00-15:20 BREAK**15:20-17:00 SESSION XVIII****CLINICAL STUDIES**

- 122** RETINAL BIOMECHANICS - A NEW PARADIGM FOR TISSUE HOMEOSTASIS
F. Ghosh, L. Taylor

- 123** POTENTIAL OPTIMAL CONDITIONS OF RETINAL PROGENITOR CELLS FROM ADULT MESENCHYMAL STEM CELLS TO BE USED FOR RETINAL IMPLANTS
D.E. Pelayes, A.M. Folgar, J.O. Zarate, G.A. Moviglia
- 124** ANATOMIC AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC VITREO-FOVEAL ADHESION. A PILOT STUDY FROM THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP
L. Wu, M.H. Berrocal, J.F. Arevalo, M. Figueroa, M. Serrano, F. Graue, A. Alezzandrini, R. Gallego, J.A. Roca, J. Dalma-Weishauz, I. Kozak, A. Colla
- 125** THE LIMPIA STUDY: A RANDOMIZED TRIAL OF SUPPLEMENTATION WITH LUTEIN, ZEAXANTHIN, OMEGA 3 FATTY ACIDS AND ANTIOXIDANTS FOR INCREASING MACULAR PIGMENT OPTICAL DENSITY IN HIGH-RISK SUBJECTS
J.F. Korobelnik, M.N. Delyfer, M.B. Rougier, H. Savel, G. Chêne, C. Delcourt, C. Creuzot-Garcher
- 126** DIRECT MEASUREMENT OF INTRARETINAL NITRIC OXIDE IN EARLY DIABETIC RETINOPATHY
W.F. Mieler, J.J. Kang-Mieler, M.J. Guthrie
- 127** MEASURING METAMORPHOPSIA IN MACULAR HOLE AND EPIRETINAL MEMBRANE
D. Yorston, G. McGowan, N. Strang, V. Manahailov
- 128** OCRIPLASMIN ADVERSE EVENT PROFILE IN CLINICAL DEVELOPMENT AND POST-MARKETING SURVEILLANCE
B.D. Kuppermann
- 129** TRANSCOROIDAL SUBRETINAL CHIP IMPLANTATION IN RP PATIENTS. THE CHOROIDAL CHALLENGE
H.G. Sachs, K.U. Bartz-Schmidt, V.P. Gabel, W. Wrobel, F. Gekeler, E. Zrenner
- 130** INITIAL RESULTS OF THE PIXIUM INTELLIGENT RETINAL IMPLANT SYSTEM (IRIS V1) IN PATIENTS WITH RETINAL DYSTROPHY
Y. Le Mer, R. Hornig, J.A. Sahel
- 131** VISUAL ACUITY IMPROVEMENT IN LOW VISION PATIENTS USING LASER PROJECTION DIVISE
B. Adiel, R. Schwartz, A. Loewenstein

17:00 ADJOURN



Conference Secretariat

Club Jules Gonin

c/o Contendam Ltd
26-28 Hammersmith Grove
London W6 7HA
UK

Tel: +44 (0)20 8748 8868

Fax: +44 (0)20 8237 4093

www.clubjulesgonin.com